Swiss National Bank Lowers Stock Position in Indivior PLC (NASDAQ:INDV)

Swiss National Bank cut its position in shares of Indivior PLC (NASDAQ:INDV) by 2.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 216,795 shares of the company’s stock after selling 5,440 shares during the quarter. Swiss National Bank’s holdings in Indivior were worth $2,782,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Indivior during the 4th quarter valued at $56,000. Stifel Financial Corp purchased a new stake in Indivior during the third quarter worth about $100,000. Melqart Asset Management UK Ltd bought a new stake in Indivior in the third quarter worth about $132,000. Jane Street Group LLC purchased a new position in Indivior in the third quarter valued at about $180,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Indivior in the third quarter valued at about $294,000. 60.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on INDV. Piper Sandler decreased their price target on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw assumed coverage on Indivior in a research note on Tuesday, January 28th. They issued a “buy” rating and a $16.00 target price on the stock.

Indivior Stock Up 1.1 %

INDV opened at $9.80 on Friday. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -28.00 and a beta of 0.82. The firm has a 50-day moving average price of $10.28 and a 200-day moving average price of $10.37. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $22.53.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.32. The business had revenue of $298.00 million for the quarter, compared to analysts’ expectations of $262.35 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. On average, sell-side analysts expect that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.